1. Home
  2. FSM vs INDV Comparison

FSM vs INDV Comparison

Compare FSM & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSM

Fortuna Silver Mines Inc (Canada)

HOLD

Current Price

$9.58

Market Cap

3.2B

ML Signal

HOLD

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$34.13

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSM
INDV
Founded
1990
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.7B
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
FSM
INDV
Price
$9.58
$34.13
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$14.00
N/A
AVG Volume (30 Days)
5.9M
1.4M
Earning Date
05-06-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
8100.00
EPS
N/A
1.64
Revenue
N/A
$1,239,000,000.00
Revenue This Year
$38.01
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.10
$20.92
Revenue Growth
N/A
4.29
52 Week Low
$5.33
$10.91
52 Week High
$13.85
$38.00

Technical Indicators

Market Signals
Indicator
FSM
INDV
Relative Strength Index (RSI) 39.91 61.79
Support Level $9.33 $33.15
Resistance Level $9.95 $35.75
Average True Range (ATR) 0.35 1.26
MACD -0.05 0.30
Stochastic Oscillator 5.93 77.51

Price Performance

Historical Comparison
FSM
INDV

About FSM Fortuna Silver Mines Inc (Canada)

Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: